Brokerages Set Evolent Health, Inc (NYSE:EVH) Target Price at $9.50

Evolent Health, Inc (NYSE:EVH) has been assigned an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.50.

A number of analysts have recently issued reports on the stock. Citigroup cut their price target on shares of Evolent Health from $6.00 to $4.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank Of Canada decreased their price objective on Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday. Needham & Company LLC lowered their price objective on Evolent Health from $15.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. UBS Group cut their target price on Evolent Health from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Truist Financial reduced their target price on Evolent Health from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EVH. Alpine Global Management LLC acquired a new stake in shares of Evolent Health during the fourth quarter valued at about $175,000. Aristides Capital LLC acquired a new position in shares of Evolent Health in the 4th quarter worth approximately $195,000. Virtu Financial LLC acquired a new position in shares of Evolent Health in the 4th quarter worth approximately $106,000. Invesco Ltd. boosted its position in shares of Evolent Health by 30.4% during the 4th quarter. Invesco Ltd. now owns 392,282 shares of the technology company’s stock worth $1,569,000 after purchasing an additional 91,370 shares during the period. Finally, nVerses Capital LLC acquired a new stake in Evolent Health in the 4th quarter valued at approximately $109,000.

Evolent Health Stock Up 6.1%

NYSE EVH opened at $3.33 on Tuesday. The business’s fifty day simple moving average is $3.50 and its 200-day simple moving average is $5.84. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 1.25. The firm has a market cap of $371.63 million, a PE ratio of -0.65 and a beta of 0.27. Evolent Health has a 52 week low of $2.50 and a 52 week high of $12.06.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The firm had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. During the same period last year, the business earned ($0.02) earnings per share. Evolent Health’s revenue was down 27.5% compared to the same quarter last year. As a group, equities analysts anticipate that Evolent Health will post 0.08 earnings per share for the current year.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.